Bilateral Primary Adrenal Non-Hodgkin Lymphoma

Vehbi Erçolak1, Oğuz Kara2, Meral Günaldı2, Çiğdem Usul Afşar2, Berna Bozkurt Duman3, Arbil Açıkalın4, Melek Ergin4, Şeyda Erdoğan4 1Harran University Faculty of Medicine, Department of Medical Oncology, Şanlıurfa, Turkey 2Çukurova University Faculty of Medicine, Department of Medical Oncology Adana, Turkey 3Adana Training and Research Hospital, Department of Medical Oncology, Adana, Turkey 4Çukurova University Faculty of Medicine, Department of Pathology, Adana, Turkey


To the Editor,
Non-Hodgkin lymphoma (NHL) is found in the adrenal gland secondarily at a rate of 25% [1]. Primary adrenal lymphoma (PAL) is found in fewer than 1% of NHL cases [2]. Secondary adrenal gland involvement is usually unilateral, while PALs are usually bilateral [3,4]. Primary adrenal gland lymphomas are usually diffuse large B-cell lymphomas (DLBCL) [1,5]. Most cases are of B-cell origin [4].
A 62-year-old male admitted to our hospital with abdominal pain in the left lumbar region persisting for 4 months without B-symptoms. Abdominal and thorax computed tomography (CT) scanning was performed and revealed a mass of 93x60 mm on the left adrenal gland and a 58-mm mass on the right adrenal gland. The mass was nonfunctional according to hormone test results. The patient underwent left adrenalectomy. The pathology specimen revealed NHL, DLBCL, leukocyte common antigen (+), CD20 (+), CD3 (-) (Figures-1A,1B). In positron emission tomography (PET)-CT, there was an advanced level of hypermetabolic mass with metastatic lymphadenopathy in the left mesenteric region and retrocrural regions (Figure-1C). There was no malignancy in PET-CT after performing 4 cycles of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy ( Figure-1D). Chemotherapy was completed in 6 doses, and 5 months after chemotherapy, the patient had no signs of clinical, laboratory, or radiological progression. Written informed consent was optained from the patient.
Nonspecific clinical presentation and imaging results make it very hard to diagnose before surgery [5]. In CT and MRI, PAL is seen as a complex mass with variable density [1]. The diagnosis of PAL is confirmed only with pathological evaluation [5].
Prognosis is usually poor. Poor prognostic factors are advanced age, large tumor size, bilateral involvement, high LDH levels, involvement of other organs, and adrenal insufficiency at admission [1,3,5,7,8]. Nongerminal B-cell phenotype and Bcl-6 rearrangement is associated with poor prognosis, as represented in the literature [2]. Patients with 3 or more risk factors (international prognostic index (IPI) scores) are accepted poor prognoses [4].
Treatment includes surgery, combination chemotherapy and radiotherapy, but bilateral adrenalectomy with adjuvant radiotherapy is still controversial [7]. Commonly used chemotherapy regimens are CHOP [8]. Response rates are relatively low and permanent remission is rare. In a review of 83 patients, the 1-year survival rate was 17.5% [4]. Full or partial treatment response is seen in only 1/3 of cases [9]. Surgical resection when used alone is related to poor prognosis in tumors with aggressive histopathological subtypes. Radiotherapy is usually not a part of treatment in the beginning, but it could be used in low-grade lymphomas and incomplete surgical excision or after chemotherapy with positive functional tumors in radiographic imaging in residual disease [4].
In conclusion, this rare disease should be kept in mind in patients with adrenal masses even in the absence of other malignancies, without nodal or extranodal involvement, or in patients with adrenal insufficiency.